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Abstract: 4-(4-Acetoxy-phenyl)-3-acetyl-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic 
acid ethyl ester (2) was synthesized by a two step reaction process. Preliminary spectroscopic analysis 
was done by IR, 1HNMR and elemental analysis. The crystal and molecular structure was further 
confirmed using single crystal x-ray diffraction. The dihedral angle between the planes of the aryl and 
dihydropyrimidine rings is 89.65(6)°, which is almost orthogonal. The dihydropyrimidine ring adopts 
twist-boat conformation.  The crystal structure is stabilized by C-H…O, N-H…S and C-H…pi 
interactions. 
Keywords: Dihydropyrimidine, crystal structure, C-H…O, N-H…S and C-H…pi weak interactions.  
Introduction 
Dihydropyrimidine-2(1H)-ones represents a heterocyclic system of remarkable 
pharmacological efficiency, including antiviral, antibacterial and anti-inflammatory 
activities. More recently dihydropyrimidines (DHPMs) have emerged as the integral 
backbones of several calcium channel modulators, anti-hypertensive agents. These 
inherently asymmetric dihydropyrimidine derivatives are not only better calcium channel 
blockers, but  have also been extensively studied to expand the existing SAR (Structure 
activity relation) and to get further insight into molecular interactions at the receptor level1-4.  
The present work is a part of our research involving a series of novel dihydropyrimidine 
derivatives which can be potent mimics of the dihydropyridines. We report here the structure 
of dihydropyrimidine derivative which is a potential calcium channel blocker. 
 The synthesis of the compound was followed by measurement of the analytical data and 
subsequent spectroscopic analysis using IR and 1H-NMR techniques to confirm the presence 
of the supposed ring system. The compound was subjected to single crystal X-ray diffraction 
analysis in order to confirm the molecular structure. 
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Experimental 
Materials 
All chemicals were obtained from a commercial source and used without further 
purification. Pale yellow colored single-crystals suitable for X-ray diffraction were obtained 
by slow evaporation method using chloroform as the solvent. 
Analytical methods 
Melting point was determined in open capillary using Guna melting point apparatus and is 
uncorrected. The IR spectra were recorded on Nicolet 400D Fourier transform–infrared (FT-
IR) using KBr pellets. 1H NMR spectra were recorded on Bruker 300-MHz FT NMR 
spectrometer in CDCl3 with TMS as internal standard and elemental analysis was carried out 
using CHNS elementar (Vario microcube). The title compound was prepared by following 
the procedure given below and as shown in Scheme.   
Procedure for the Preparation of the title compound (2) 
Compound 1 (2.0 g) was mixed with acetic anhydride (10 mL) refluxed for about 4 hours. 
The reaction mixture was cooled and diluted by addition of water (20 mL). The solid 
separated was washed with water, filtered, dried (Yield: 1.92g, 85% and mp 157 0C). Pale 
yellow crystals of the title compound 2 were obtained for diffraction by slow evaporation 
from a solution in chloroform.  
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Scheme 1. Synthesis of 4-(4-Acetoxy-phenyl)-3-acetyl-6-methyl-2-thioxo-1,2,3,4-tetrahydro-
pyrimidine-5-carboxylic acid ethyl ester. 
Physical measurements 
IR(KBr) ν cm-1 : 3098, 2996, 1705, 1714, 1643, 1512, 1054. 1H NMR (CDCl3): δ 1.29 (t, 
J=7.2 Hz, 3H,-CH2CH3), 2.06 (s, 3H, CH3), 2.19 (s, 3H, CH3), 2.46 (s, 3H, CH3), 4.19 (q, 
J=7.2 Hz, 2H, CH2CH3), 5.96(S, 1H, CH), 6.92–7.56 (m, 4H, ArH) 8.32 (s, 1H, NH).  
%CHNS calc/found: C, 57.43/57.33; H, 5.36/5.32; N, 7.44/7.53; S, 8.52/8.41. m/z: 376. 
Investigation techniques 
X- ray diffraction 
The X‐ray diffraction data for the compound 2 was collected on a Bruker Smart CCD Area 
Detector System, using MoKα (λ=0.71073 Å) radiation. Intensity data was collected up to a 
maximum of 26.99° in the ω–ф scan mode. The data was reduced using SAINT-Plus5. The 
structure was solved by direct method using SHELXS976 and difference Fourier synthesis 
using SHELXL976. The positions and anisotropic displacement parameters of all non-
hydrogen atoms were included in the full‐matrix least‐square refinement using SHELXL976 
and the procedures were carried out for a few cycles until convergence was reached. A total 
of 19001 reflections were collected, resulting in 3843 [R(int) = 0.0405] independent 
reflections of which the number of reflections satisfying I>2σ(I) criteria was 3130. These 
were treated as observed. The H atoms were placed at calculated positions in the riding  
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model approximation (C‐H = 0.93 Å), with their temperature factors set to 1.2 times those of 
the equivalent isotropic temperature factors of the parent atoms. All other non‐H atoms were 
refined anisotropically. The R factor for observed data finally converged to R = 0.0434 with 
wR2 = 0.1040 in the compound. The maximum and minimum values of residual electron 
density were 0.372 and -0.290eÅ‐3. Molecular diagram was generated using ORTEP7.  The 
mean plane calculation was done using the program PARST8. 
Table 1.  Crystal data and structure refinement of compound 2 
                Empirical formula                         C18 H20 N2O5S 
               Formula weight                                  376.42 
               Temperature                                          296(2) K 
       Wavelength                                          0.71073 A 
       Crystal system, space group                Triclinic, P ī 
       Unit cell dimensions               
       a                  7.8163(3)Å                       
       b                 9.5961(5)Å       
       c               12.4869(7)Å   
       α (°)                77.286(5) 
       β (°)                83.282(4) 
        γ (°)               76.171(4) 
       Volume                                                        885.09(8) Å3 
       Z,                                                                  2  
      Calculated density (Mg/m3)                         1.412  
       Absorption coefficient (mm-1)                        0.215  
       F(000)                                                          396 
       Crystal size                                                  0.18 x 0.16 x 0.16 mm 
       Theta range for data collection                   2.51 to 26.99 deg. 
       Limiting indices                                     -9<=h<=9, -12<=k<=14, -15<=l<=15 
       Reflections collected / unique                19001 / 3843 [R(int) = 0.0405] 
       Completeness to theta                                 26.99     99.8 % 
       Max. and min. transmission                        0.9664 and 0.9623 
       Refinement method                                     Full-matrix least-squares on F2 
       Data / restraints / parameters                      3843 / 0 / 239 
       Goodness-of-fit on F2                             1.000 
       Final R indices [I> 2sigma (I)]                    R1 = 0.0434, wR2 = 0.1040 
       R indices (all data)                                       R1 = 0.0575, wR2 = 0.1119 
       Largest diff. peak and hole (e.A-3)               0.372 and -0.290  
Results and Discussion 
The intermediate 4-(4-acetoxy-phenyl)-3-acetyl-6-methyl-2-thioxo-1,2,3,4-tetrahydro-
pyrimidine-5-carboxylic acid ethyl ester (1) was synthesized by Biginelli reaction which is a 
one-pot, acid-catalyzed condensation reaction. Compound 1 was acylated using acetic 
anhydride, forming 2 (Scheme 1).  Examination of analytical data of C, H, N and S content 
of the compound are in good agreement with calculated values based on proposed structure 
shown in scheme. Formation of compound 2
 
was confirmed by the absence of one NH and 
OH peak around δ 7.6 – 10.3 ppm and appearance of two singlets for 6H at δ 2.06, 2.19 ppm 
in the 1H NMR spectra. It was further confirmed by a sharp peak at 3251cm-1 in the IR 
spectrum due to the presence of another free NH group. 
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Crystallography 
Summary of crystallographic data and other structure refinement parameters of the title 
compound are given in Table 1. Table 2 gives the respective hydrogen bonding parameters. 
The ORTEP view of the molecule with atomic labeling (thermal ellipsoids drawn at 50% 
probability) is shown in Figure 1. Figure 2 and 3 show the packing of molecules in the 
crystal structure.     
 
 
 
 
 
Figure 1. Ortep view of compound 2, 
showing 50% Probability ellipsoids 
and the atom-numbering scheme. 
Figure 2. Packing of the molecules in crystal of 2 
viewed along ‘C’ axis. Dotted lines indicate C-
H...O intermolecular interactions; the hydrogens are 
omitted for clarity. 
 In the title compound, the ethyl carboxylate and the methyl group lie on the left side of the 
dihydropyrimidine ring, whereas the acetyl and the thioxo groups are on the other side of the ring. 
The methoxy substituted aryl ring is positioned perpendicular to dihydropyrimidine ring9. The 
dihedral angle between the planes of the aryl and dihydropyrimidine rings is 89.65(6)°, which 
predisposes the molecule towards the excellent receptor-binding properties. Dihydropyrimidine of 
this type is known to show conformational flexibility, where as the aryl ring and the ester group 
can rotate and the conformation of dihydropyrimidine ring can change10-11.   
 This ‘aryl-group up’ configuration is considered crucial for the enhanced calcium 
antagonist activity in this compound12. The 4-aryl substituent (methoxy group) adopts a 
synperiplanar conformation with respect to C4-H4 bond. These features have been found 
mandatory for optimum calcium channel modulatory activity13. The central 
dihydropyrimidine ring is significantly puckered, assuming a conformation of twisted boat 
similar to those, reported earlier14. The plane calculation shows that the atoms C4 and N2 
deviate from the mean plane N1/C2/C5/C6 constituting the ring by 0.3524(2)Å and -
0.2168(2)Å respectively, indicating that the conformation of the ring is that of a twisted 
boat, with the atoms C4 and N2 being displaced by this overall planarity of the rest of the 
ring. The ring puckering parameters for the dihydropyrimidine ring in the title compound are 
Q (2) = 0.486 (2) Å φ (2) = -16.42 (2)° and θ= 109.14 (2)° respectively.  
 The molecular structure is primarily stabilized by intramolecular C7-H7A…O1 
hydrogen bond leading to the formation of a six-membered hydrogen bonded pattern 
corresponding to graph set S(6)15 thus locking the molecular conformation and eliminating 
conformational flexibility. The crystal structure is further stabilized by two types of 
intermolecular C-H…O interactions. Both the C-H…O interaction results in the formation of 
head to head centrosymmetric dimers corresponding to a graph set of R22(24) along b’ axis 
and R22(12)15 along ‘c’ axis respectively (Figure 2).  
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Additionally the crystal structure is stabilised by N-H…S intermolecular interaction 
resulting in the formation of dimers along ‘c’ axis (Figure 3). The molecular packing is 
further stabilized by pi-pi stacking interactions between the pyrimidine rings. The C5-C6 
disposed at a distance of 3.825(3) Å. In addition pi-ring interaction of the type C-H…Cg1 
(Cg1 being the centroid of the ring C11-C16) is also observed in the crystal structure (Table 2). 
 
Figure 3. Packing of the molecules in crystal of 2. Dotted lines indicate, N-H….S 
intermolecular interaction. 
Table 2.  Non-bonded interactions and possible hydrogen bonds (Å, °) for  Compound 2.                                    
(D-donor; A-acceptor; H-hydrogen) 
D—H· ·  ·A D—H H· ·  ·A D· ·  ·A D—H· ·  ·A 
C7-H7A...O10 
N1-H1...S1i 
C7-H7B…O2ii               
C18-H18B...O3iii 
C10-H10B…Cg1iv
 
  
0.960   
0.860 
0.960   
0.960 
0.960 
2.193 
2.569 
2.818                
2.769                
2.893 
2.914(2) 
3.366(2) 
3.645(2)   
3.571(3)                  
3.725(4) 
131 
155 
145 
141  
145 
Symmetry code: (0) x, y, z  (i) -x, -y, -z+1 (ii) -x, -y+1, -z+1 (iii) -x, -y+1, -z (iv) -x, 1-y, -z                                         
Conclusion 
The synthesis as well as the characterization of 4-(4-Acetoxy-phenyl)-3-acetyl-6-methyl-2-
thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester is described. 
Additionally, the single crystal X-ray diffraction analysis revealed certain interesting 
features such as the non-planarity of the molecule, intermolecular weak interactions and 
supramolecular assembly.  
Supplementary material 
The CIF file is deposited at the Cambridge Crystallographic Data Centre, The deposition 
number of compound 2 is CCDC-875843.  
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